Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $32.0052W HIGH $117.71
Volume
464.90 K
Value Traded
66.61 M
Short % Float
12.39%
Days to Cover
3.8
+0.66%Week
+15.23%1 Month
+33.04%3 Month
+38.31%6 Month
+198.88%5 Year
+198.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.84 B
EPS (TTM)
-69.60
P/E Ratio
-
Ent. Value
5.02 B
Total Shares
41.76 M
Float Shares
29.86 M
Insiders
28.54%
Institutions
70.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MANE Catalyst Timeline
Dated clinical, regulatory and corporate events for Veradermics, Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Veradermics, Incorporated
53Total events
9Upcoming
15Tier-1 (high impact)
2025 to 2043Coverage
Upcoming catalysts 2
Event history 41
▲Topline ReadoutVDPHL01Clinical Data
Positive topline results from Part A of Phase 3 Study '304' in male pattern hair loss
male pattern hair losssource ↗
●R&D DayVDPHL01Presentation
Investor call and live webcast to review Phase 3 '304' Part A results
mild-to-moderate pattern hair losssource ↗
▲Primary Endpoint MetVDPHL01Clinical Data
Study '304' met co-primary endpoints of non-vellus TAHC and AAIRS PRO at Month 6
male pattern hair losssource ↗
▲Enrollment CompleteVDPHL01Trial
Completed participant enrollment in female pattern hair loss Study '306'
female pattern hair losssource ↗
◆Oral PresentationVDPHL01Presentation
Oral presentation of subgroup analysis data from Phase 2/3 Study '302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss
pattern hair losssource ↗
◆Poster PresentationVDPHL01Presentation
Poster presentation of subgroup analysis data from Phase 2/3 Study '302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss
pattern hair losssource ↗
◆Oral PresentationVDPHL01Presentation
Investor call to discuss Phase 2 results of VDPHL01 in females
mild-to-moderate pattern hair losssource ↗
▲Topline ReadoutVDPHL01Clinical Data
Positive topline results from Phase 2 Study '207' of VDPHL01 in female pattern hair loss
female pattern hair losssource ↗
▲Primary Endpoint MetVDPHL01Clinical Data
VDPHL01 met hair growth and patient-reported outcome endpoints at Month 6 in Study '207'
female pattern hair losssource ↗
▲Safety Data UpdateVDPHL01Clinical Data
VDPHL01 demonstrated favorable safety profile with no treatment-related SAEs or cardiac AESIs in Study '207'
female pattern hair losssource ↗
◆Full ResultsVDPHL01Clinical Data
Twelve-month data from Study '302' anticipated
pattern hair losssource ↗
▲Topline ReadoutVDPHL01Clinical Data
Positive topline results from open-label Phase 2 Study '207' in female pattern hair loss
female pattern hair losssource ↗
●Quarterly UpdateCorporate
Reported financial results for the second quarter ended June 30, 2026
◆Poster PresentationVDPHL01Presentation
Poster presentation of topline results from Phase 2/3 '302' study of VDPHL01 at 2026 World Congress for Hair Research
androgenetic alopeciasource ↗
◆Poster PresentationVDPHL01Presentation
Two poster presentations on VDPHL01 at 2026 Music City SCALE Symposium
▼Equity OfferingCorporate
Raised approximately $472.0 million in aggregate gross proceeds through follow-on offering and concurrent private placement
▼Equity OfferingCorporate
Private placement of 300,000 pre-funded warrants to Suvretta Capital for ~$30M
▼Equity OfferingCorporate
Launch of proposed public offering of 3,350,000 shares of common stock and pre-funded warrants
▲Topline ReadoutVDPHL01Clinical Data
Positive topline results from Part A of Phase 2/3 Study '302' of VDPHL01 in male pattern hair loss
male pattern hair losssource ↗
◆Topline ReadoutVDPHL01Clinical Data
Topline results from Phase 2/3 '302' study of VDPHL01
mild-to-moderate pattern hair losssource ↗
◆Oral PresentationVDPHL01Presentation
Conference call to discuss topline results from Phase 2/3 '302' study
mild-to-moderate pattern hair losssource ↗
▲Topline ReadoutVDPHL01Clinical Data
Positive topline results from Part A of Phase 2/3 Study '302' in male pattern hair loss
male pattern hair losssource ↗
◆Full ResultsVDPHL01Clinical Data
Twelve-month data from Study '302' anticipated
pattern hair losssource ↗
▲Enrollment CompleteVDPHL01Trial
Completion of patient enrollment in Phase 2/3 Study '306' in females with pattern hair loss
female pattern hair losssource ↗
◆Oral PresentationPresentation
Veradermics management to participate in Jefferies Biotech on the Beach Summit
◆Oral PresentationPresentation
Veradermics management to participate in fireside chat at Leerink Partners Global Healthcare Conference
▲Enrollment CompleteVDPHL01Trial
Completed enrollment in second Phase 3 trial (304) for male pattern hair loss
male pattern hair losssource ↗
●IpoCorporate
Pricing of upsized initial public offering of 15,077,647 shares at $17.00 per share
▲Enrollment CompleteVDPHL01Trial
Enrollment completed in Phase 3 Study '304' of VDPHL01 in male pattern hair loss
male pattern hair losssource ↗
▲Equity OfferingCorporate
Upsized IPO and follow-on financing raised approximately $766.8 million
▲Enrollment CompleteVDPHL01Trial
Completed enrollment in first Phase 2/3 trial for male pattern hair loss
male pattern hair losssource ↗
Past FDA Catalysts and PDUFA Decisions
How MANE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-19 | VDPHL01 | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 36%
Small Cap(rank 237 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VDPHL01 Small moleculeNCT06724614 | Androgenetic Alopecia | Phase 3 | ACTIVE NOT_RECRUITING | 1,582 | Sep 1, 2026 | ||||||
| VDMN-21 Patch Low Dose Small moleculeCompletedNCT05799157 | Verruca Vulgaris | Phase 2 | COMPLETED | 153 | Feb 25, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every MANE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VDPHL01 | male pattern hair loss | Phase 3 | 2026-10-19 | early and robust hair growthRead More | Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair LossRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLCDirector | Sell | -690,601 2,957,937 held | $107.25 | 08/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MANE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 3.6 % (620 %) | 245.88 M | 2.00 M | 300% ( 1.50 M) |
MANE Institutional Ownership Trends
MANE Short Interest
Shares sold short, counted twice a month.
12.39%
Short % of Float
of tradable shares sold short
3.7M
Shares Sold Short
-12.9% vs prior count
3.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
982.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MANE ranks across every disease it competes in
Competitive Position is a premium feature
See how MANE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMANE News
MANE▲ +12.4%on this news· ran to +27% by day 3
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
Veradermics announced positive results from its Phase 3 clinical trial of VDPHL01, an oral treatment for male pattern hair loss. The trial met all primary and secondary endpoints, showing significant hair growth and improvement in patient-reported outcomes. With a favorable safety profile, VDPHL01 positions itself as a potential first FDA-approved non-hormonal oral treatment for pattern hair loss in men.
Read more →MANE▲ +12.4%on this news· ran to +27% by day 3shared move
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics will host a conference call on October 19, 2026, to discuss the topline results from its Phase 3 clinical trial of VDPHL01, a new treatment for mild-to-moderate pattern hair loss in men. The trial involved over 500 participants and aims to provide insights into the drug's efficacy and safety. VDPHL01 could become the first FDA-approved oral non-hormonal treatment for this condition.
Read more →MANEVeradermics to Present at Upcoming September Investor Conferences
Veradermics, a late-stage biopharmaceutical company, has announced its participation in key investor conferences in September 2026. The company, which specializes in therapeutics for pattern hair loss, will present at the Wells Fargo 21st Annual Healthcare Conference and the Citi's 2026 Biopharma Back to School Conference. This engagement highlights Veradermics' commitment to connecting with the investment community.
Read more →MANEVeradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics, a late-stage biopharmaceutical company, reported its second quarter financial results for 2026, showcasing advancements in its product VDPHL01 aimed at treating female pattern hair loss. The company highlighted key milestones reached in its clinical development, indicating a positive trajectory for its therapeutic innovations.
Read more →MANE▲ +5.2%on this news
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Veradermics, a biopharmaceutical company, announced the presentation of data from its Phase 2/3 Study '302' focusing on VDPHL01 for male patients with pattern hair loss. The subgroup analysis was presented on July 16, 2026, and will continue with an oral presentation on July 17, 2026, at the American Academy of Dermatology Innovation Academy.
Read more →MANE▲ +12.3%on this newsshared move
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
Veradermics, Incorporated announced positive topline results from its Phase 2 clinical trial of VDPHL01, an oral minoxidil formulation for female pattern hair loss. The trial demonstrated effectiveness in females with mild-to-moderate hair loss. This development positions VDPHL01 as a potential first FDA-approved oral treatment for this condition, with further studies planned.
Read more →MANE▲ +12.3%on this newsshared move
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
Veradermics, a biopharmaceutical company, will hold a conference call on July 15, 2026, to discuss the results of its Phase 2 clinical trial, Study '207'. This study evaluates VDPHL01, an oral minoxidil tablet, in females with mild-to-moderate pattern hair loss. The call aims to inform investors about the findings from the female treatment arms.
Read more →MANEVeradermics to Present at Upcoming June 2026 Investor Conferences
Veradermics, a biopharmaceutical company focused on pattern hair loss, will present at investor conferences in June 2026. Their lead product, VDPHL01, is in Phase 3 development and aims to be the first FDA-approved oral non-hormonal treatment for this condition. The company highlights the significant market demand for effective treatments for pattern hair loss.
Read more →MANEVeradermics to Present at Upcoming June Investor Conferences
Veradermics is set to present at several investor conferences in June. The details of the presentations and the conferences have not been disclosed in the article. This announcement indicates the company's ongoing engagement with investors and the market.
Read more →MANEVeradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research
Veradermics has announced a poster presentation regarding the topline results from their Phase 2/3 study of VDPHL01. This presentation will take place at the 2026 World Congress for Hair Research. The announcement highlights the company's ongoing research efforts in hair restoration treatments.
Read more →MANEVeradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Veradermics has announced two poster presentations regarding VDPHL01 at the upcoming 2026 Music City SCALE Symposium. The details of the presentations and their implications for the research community remain unspecified in the announcement.
Read more →MANEVeradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics has released its financial results for the first quarter of 2026, highlighting recent corporate and clinical advancements. The report outlines the company's financial performance and any significant developments in their clinical programs. Further details on specific achievements or challenges were not disclosed in the article.
Read more →MANE▼ -7.1%on this news
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
Veradermics has announced the pricing of an upsized public offering of 3,843,790 shares at $100.00 each, aiming to raise approximately $384.4 million. Additionally, the company is conducting a private placement of 300,000 pre-funded warrants for about $30 million. Both offerings are expected to close on May 1, 2026, subject to customary conditions.
Read more →MANE▲ +47.6%on this newsshared move
Veradermics Announces Launch of Public Offering
Veradermics has announced the launch of a public offering, indicating a strategic move to raise capital. The details regarding the offering, including the number of shares and pricing, have not been disclosed. This announcement reflects the company's ongoing efforts to enhance its financial position.
Read more →MANE▲ +47.6%on this newsshared move
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
Veradermics, Incorporated has reported positive topline results from its Phase 2/3 clinical trial of VDPHL01, an oral minoxidil formulation. The trial involved over 500 males with mild-to-moderate pattern hair loss. The results indicate early and robust hair growth, showcasing the potential of this innovative treatment.
Read more →MANE▲ +47.6%on this newsshared move
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics is set to hold a conference call to discuss the topline results from their Phase 2/3 study of VDPHL01, a treatment for males experiencing mild-to-moderate pattern hair loss. This call aims to provide insights into the study's findings and implications for future developments.
Read more →MANE▼ -7.1%on this news
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
Veradermics has reported its financial results for the fourth quarter and full year of 2025. The company also highlighted recent corporate and clinical updates. However, specific details regarding financial performance and clinical developments were not disclosed in the article.
Read more →MANEVeradermics to Participate in Upcoming March Investor Conferences
Veradermics, a late clinical-stage biopharmaceutical company, will participate in two investor conferences in March 2023. CEO Reid Waldman will engage in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami. The company is focused on developing treatments for aesthetic and dermatological conditions, including its lead program for pattern hair loss.
Read more →MANEVeradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
Veradermics has completed enrollment in its second Phase 3 clinical trial for VDPHL01, an oral treatment for male pattern hair loss. This milestone includes over 1,000 participants across both trials. VDPHL01 aims to enhance hair restoration while minimizing cardiac risks. The company is advancing towards its first NDA filing for an oral treatment in nearly three decades.
Read more →MANEVeradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
Veradermics, a late clinical-stage biopharmaceutical company, has successfully closed its upsized initial public offering, selling 17,339,294 shares at $17.00 each. The offering generated approximately $294.8 million in gross proceeds. The shares are now trading on the New York Stock Exchange under the ticker symbol 'MANE'.
Read more →About Veradermics, Incorporated
Headquarters470 JAMES STREET, NEW HAVEN, CT, 06513
BIOPHARMAWATCH ELITE PLUS
Trade the next MANE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime